Similar companies
Income Statement (NONE)
| Q2 '25 | QoQ | |
|---|---|---|
| Revenue | 3.1M | 11% |
| Operating expense | 28M | 1.1% |
| Net Income | -24M | 0.7% |
Balance Sheet (NONE)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 85M | 24.8% |
| Total Liabilities | 138M | 3.9% |
Cash Flow (NONE)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | -23M | 22.9% |
| Cash from investing | 400,000 | 98.5% |
| Cash from financing | -3.1M | 0.9% |
EPS
Financial Highlights for Mersana Therapeutics in Q2 '25
Mersana Therapeutics reported a revenue of 3.1M, which is a 11% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Operating Expenses for this period were 28M, showing a 1.1% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -24M, showing a -0.7% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
Mersana Therapeutics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
